Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Recce Shareholders Reject Remuneration Report In Second Strike, But Block Board Spill

RCE: $0.330 +0.00% · MC: $113M

Recce Pharmaceuticals shareholders delivered a second strike against the remuneration report, with more than a quarter of votes cast opposing it, but rejected the spill resolution. The AGM presentation said patient dosing is underway in Phase 3 trials of RECCE 327 Gel in Australia and Indonesia, with an independent committee expected to review Indonesian trial data as soon as mid-November; the company also reported an exclusive Australian and New Zealand licensing deal and a non-binding Middle East term sheet.

Source announcements: 2026-11-06 08:24 to 2026-11-06 13:27 Sydney time
Story updated 2026-11-06 13:32 Sydney time
SourcesAGM PresentationResults of Meeting
Comments